Brought to you by 
Tengion gets $50mm with Series B round
29 Jun 2006
Executive Summary
Tengion (developing autologous neo-organs and tissues for the cardiovascular and genitourinary markets) has raised $50mm with its Series B venture round. Bain Capital (with funds from Brookside Capital) and Quaker BioVentures led the financing and were joined by all of the company's current backers, namely Oak Investment Partners, Johnson & Johnson Development Corp., HealthCap, and L Capital Partners. Tengion plans to use the proceeds to advance its autologous neo-bladder, and to develop a manufacturing facility in PA.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tengion gets $50mm with Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice